Evidence map›Paper›PMID 38590799›Full record

ArticleOncoimmunology2024

CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy.

Ayush Pant, Brandon Hwa-Lin Bergsneider, Siddhartha Srivastava, Timothy Kim, Aanchal Jain, Sadhana Bom, Pavan Shah, Nivedha Kannapadi, Kisha Patel, John Choi and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. MDSC: a new potential breakthrough in CAR-T therapy for solid tumors.Cell communication and signaling : CCS · 2024
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Ayush PantDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Brandon Hwa-Lin BergsneiderDepartment of Neurosurgery, Stanford School of Medicine, Palo Alto, CA, USA.
Siddhartha SrivastavaDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Timothy KimDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Aanchal JainDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sadhana BomThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pavan ShahDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nivedha KannapadiDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kisha PatelDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
John ChoiDepartment of Neurosurgery, Stanford School of Medicine, Palo Alto, CA, USA.
Kwang Bog ChoDepartment of Neurosurgery, Stanford School of Medicine, Palo Alto, CA, USA.
Rohit VermaDepartment of Neurosurgery, Stanford School of Medicine, Palo Alto, CA, USA.
Caren Yu-Ju WuDepartment of Neurosurgery, Stanford School of Medicine, Palo Alto, CA, USA.
Henry BremDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Betty TylerDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Drew M PardollThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Christina JacksonDepartment of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Michael LimDepartment of Neurosurgery, Stanford School of Medicine, Palo Alto, CA, USA.
Johns Hopkins University · USStanford Medicine · USJohns Hopkins Medicine · USHospital of the University of Pennsylvania · USSidney Kimmel Comprehensive Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has revolutionized the treatment of cancers. Reinvigorating lymphocytes with checkpoint blockade has become a cornerstone of immunotherapy for multiple tumor types, but the treatment of glioblastoma has not yet shown clinical efficacy. A major hurdle to treat GBM with checkpoint blockade is the high degree of myeloid-mediated immunosuppression in brain tumors that limits CD8 T-cell activity. A potential strategy to improve anti-tumor efficacy against glioma is to use myeloid-modulating agents to target immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. We found that the co-inhibition of the chemokine receptors CCR2 and CCR5 in murine model of glioma improves the survival and synergizes robustly with anti-PD-1 therapy. Moreover, the treatment specifically reduced the infiltration of monocytic-MDSCs (M-MDSCs) into brain tumors and increased lymphocyte abundance and cytokine secretion by tumor-infiltrating CD8 T cells. The depletion of T-cell subsets and myeloid cells abrogated the effects of CCR2 and CCR5 blockade, indicating that while broad depletion of myeloid cells does not improve survival, specific reduction in the infiltration of immunosuppressive myeloid cells, such as M-MDSCs, can boost the anti-tumor immune response of lymphocytes. Our study highlights the potential of CCR2/CCR5 co-inhibition in reducing myeloid-mediated immunosuppression in GBM patients.

Indexed as

Brain NeoplasmsGlioblastomaGliomaMyeloid-Derived Suppressor CellsAnimalsHumansMiceMyeloid CellsReceptors, CCR2Receptors, CCR5Tumor MicroenvironmentCCR2 protein, humanCCR5 protein, humanReceptors, CCR2Receptors, CCR5GliomaImmunotherapyMDSC

Identifiers

PMID38590799
PMCPMC11000615
OpenAlexW4393983888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.